Global Leader in CLD
KBI Biopharma's SUREtechnology Platform™, powered by Selexis®, ranks as a global leader in mammalian cell line development (CLD)
Trusted European Partner
Located in the heart of Europe's Health Valley and in close proximity to Switzerland, France, and Italy, our diverse and multicultural team represents 20+ nationalities. In fact, we likely speak your language!
Track Record of Success
The SUREtechnology Platform™, created in Geneva, has produced cell lines for 10 commercialized products and 170+ additional products that are currently in pre-clinical and clinical trials
Pioneer in Single-Use
KBI Biopharma has a history of innovation and was the first CDMO to introduce in 2012 the 2000L scale Xcellerex™ single-use bioreactor that de-risks development
100% Batch Success Rate
In its first year of operations, KBI Biopharma Geneva has manufactured and released 5 batches with a 100% success rate
Advanced Cell Line Development
Leveraging advanced gene technology and a proprietary CHO-based cell line to meet the challenges of cell line development (CLD)
At KBI Biopharma, we are your global partner for mammalian-based biopharmaceutical development here in the heart of Europe.
By combining our proprietary SUREtechnology Platform with our world-class expertise, our CLD services significantly streamline the development of high-performance mammalian cell lines for therapeutic protein production. As a cornerstone of the SUREtechnology Platform, the KBI Biopharma SURE CHO-M Cell Line™ is a proprietary, high-performance cell line derived from CHO-K1 cells and used for the production of biotherapeutics.
Our SUREmAb™ offering is specifically designed for accelerated, efficient monoclonal antibody (mAb) development that is robust and secured. SUREmAb™ delivers high titers (up to 10 g/L) with lower-cost workflows enabling RCB development in as little as 9 weeks, and drug substance release in 11 months.
Delivering the data and insights you need, the reliability and performance you expect, and the global regulatory compliance you require.
World-Class Analytical Support and Services
Depth of knowledge to future-proof your program with sustained excellence for every molecule at every stage of development
We are fully equipped for release and stability analysis of drug substances, drug products, excipients, and diluents. We have all the relevant characterization capabilities, including GMP-qualified instrumentation and procedures for mass spectrometry and cell-based assay, combined with the expertise of the KBI Biopharma team and versatile product exposure.
We empower biopharmaceutical innovation with cutting-edge analytics and the highest quality standards to expedite product development.
- Our GMP-grade mass spectrometry services help you develop products, faster
- Our GMP-grade cell-based assay capabilities enable a deeper understanding of your product
- Our in-house experts include a trained pharmacist performing clinical in-use studies
- The Geneva facility is part of a global network within KBI Biopharma for access to experts wherever you are in the world
Robust cGMP Manufacturing Capacity
For seamless, integrated project process from early development to cGMP Drug Substance certificate of fill
Our Geneva facility strategically combines operations under one roof for vertically-integrated services supporting First in Human (FIH) programs from CLD through to commercial manufacturing. Our depth of experience and expertise in mammalian-based expression streamlines the creation of new biologics and breaks through common bottlenecks and barriers.
We care about your success, and our highest priority is to keep your project on-track, never letting limited capacity or technical issues slow you down.
- We ensure your work keeps moving forward, in a timely manner, with our open capacity and widespread network of facilities across the EU and US
- We continually mitigate risks, taking on right from the start derisking strategies, including our pioneering use of single-use bioreactor systems that shrinks the risk of cross-contamination in our Geneva facility
- With more than 300 individual CLD programs, 170+ drug candidates (ranging from pre-clinical to commercial), and 100 investigational new drugs (INDs) supported, you are not just choosing a CDMO partner — you are joining a legacy of success
